NEWS
LATEST
FULL LIST
-
Further Unlocking the Potential of 4D Bioprinting for Heart Tissue Engineering
4D Bioprinting: Not a New Concept, But What Makes This Study Unique? The concept of 4D bioprinting—creating printed constructs that transform over time—has been around for over a decade. However, recent work, in Advanced Functional Materials out of Andrew Daly’s lab, are pushing the boundaries of this technology by integrating cell biology, computational modeling, and…
-
Aspect Biosystems Secures $115M Series B to Advance Bioprinted Tissue Therapeutics
Aspect Biosystems, a biotechnology leader in bioprinted tissue therapeutics, has announced the successful close of a $115 million Series B funding round. The financing, led by Dimension—a firm specializing in technology and life sciences—featured contributions from a diverse group of investors, including Novo Nordisk, Radical Ventures, InBC, and others. This round marks a significant step…
-
Stanford Open Source 3D Extrusion Bioprinter By Mark Skylar-Scott Lab
3D bioprinting has the potential to become as commonplace as PCR machines or FDM 3D printers—accessible, modular, and easy to use. Recognizing this potential, Mark Skylar-Scott and his team have developed The Printess, a new printer featured in their latest paper in Advanced Materials. Designed for engineers, scientists, and educators, The Printess is a $250…
-
JOIN C-STARS: Exploring the Future of Space BioFabrication and Manufacturing
The space economy is on the brink of transformation, with the global market expected to surpass $1 trillion by 2030. At the forefront of this change is the Center for Science, Technology, and Advanced Research in Space (C-STARS), a groundbreaking initiative set to redefine space manufacturing and exploration. Vision and Mission of C-STARS C-STARS aims…
-
EpiBone Secures Funding Convertible Note to Drive Global Expansion of Clinical Trials
EpiBone, Inc., a regenerative medicine company specializing in skeletal reconstruction, has completed a convertible note funding round led by Kendall Capital Partners, with participation from LifeSpan Vision Ventures, EMV Capital plc, and other strategic investors. The specific amount raised in this round has not been disclosed. However, prior to this funding, EpiBone had secured approximately…
-
Engineering the Future of Vascularized Tissues: Programmable Bioinks Take Center Stage
In tissue engineering, the development of functional vascular networks remains one of the greatest challenges. Vascularization—the formation of blood vessel networks—is essential for delivering nutrients, oxygen, and waste removal in any tissue construct intended for clinical use. A recent study, published in Advanced Healthcare Materials, introduces an approach that leverages programmable bioinks to assort vascular…
-
Carl Roth Partners with BIO INX to Advance 3D Bioprinting Accessibility
Carl Roth, a leading distributor of laboratory products, has partnered with BIO INX to offer its full portfolio of bioinks through Carl Roth’s distribution network. This collaboration marks Carl Roth’s entry into the 3D bioprinting space, aiming to streamline logistics and increase the accessibility of innovative bioprinting solutions globally. BIO INX’s life sciences bioinks stand…
-
French Based Lattice Medical Wins Coveted US MedTech Innovator Mid-Stage Grand Prize
Lattice Medical took center stage at the 2024 MedTech Innovator Mid-Stage Grand Prize competition, securing $200,000 in non-dilutive cash proceeds. This recognition not only validates Lattice Medical’s groundbreaking work in breast reconstruction but also spotlights the potential of bioprinting in healthcare. Lattice Medical breast implant shown above. The Winning Innovation: MATTISE 3D-Printed Breast Implant Lattice…
-
CELLINK’s Strategic Shift: Right-Sizing for Long-Term Profitability
In a significant move towards financial sustainability and strategic focus, CELLINK Bioprinting AB, a subsidiary of the BICO Group, has announced plans to reshape its operational framework. The bioprinting leader aims to right-size its organization and sharpen its commercial agenda, a decision that reflects broader industry trends toward streamlined operations and targeted growth in life…
-
Cellbricks Therapeutics Expands to the U.S., Launches Subsidiary in Cambridge, MA
In a significant move that bridges two of the world’s leading biotech ecosystems, Cellbricks Therapeutics, a Berlin-based tissue therapeutics pioneer, has launched a new U.S. subsidiary in Cambridge, Massachusetts. The event, marked by a ribbon-cutting ceremony, featured distinguished guests including Berlin’s Governing Mayor, Kai Wegner, Deputy Mayor and Senator for Economics, Franziska Giffey, and State…
Subscribe
Enter your email below to receive updates.
The Business of Biofabrication 